Med. praxi. 2017;14(4):50-55

Sphincter dysfunction in patients with multiple sclerosis

MUDr. Miroslava Ryšánková
Urologická klinika LF UK a FN Hradec Králové

Multiple sclerosis (MS) is a disease mainly affecting younger individuals aged 20 to 40 years. It is a chronic inflammatory diseaseof the central nervous system (CNS). The first symptoms of the disease most common sensory, otor or visual diffculties. Many patientsdevelop early urological problems, in particular sphincter dysfunction. Therefore, it is necessary for a urologist to considerMS in young patients with these complaint and, if this is lacking, to evaluate the patient neurologically.

Keywords: multiple sclerosis, neurogenic bladder, sphincter, incontinence, urine retention, postvoid residual volume

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšánková M. Sphincter dysfunction in patients with multiple sclerosis. Med. praxi. 2017;14(4):50-55.
Download citation

References

  1. Andersson KE. Antimuscarinic mechanism and the overactive detrusor: an update. Eur. Urol., 2011; 59: 377-386. Go to original source... Go to PubMed...
  2. Blavais JG, Bhimani G, Labib KB. Vesicourethral dysfunction in multiple sclerosis. J Urol 1979; 122: 342. Go to original source... Go to PubMed...
  3. Burešová J, Vidlář A. Močové dysfunkce u pacientů s roztroušenou sklerózou. Urol. praxi, 2014; 15(5): 241-243.
  4. Djakovic N, Hubert J, Nyarangi-Dix J, Hohenfellner M. Artificial sphincter for the treatment of incontinence, Urologe A, 2010; 49(4): 515-524. Go to original source... Go to PubMed...
  5. Dufek M. Roztroušená skleróza - EDSS (expanded disability status scale), tzv. Kurtzkeho škála. Neurol. praxi 2011; 12(Suppl. G): 6-9.
  6. Horáková D. Roztroušená skleróza a úloha praktického lékaře. Med. praxi 2008; 5(10): 378-382.
  7. Koldewijn EL, Hommes OR, Lemmens WAJG, Debruyne FMJ, Van Kerrebroek PEV. Relation between lower urinary abnormalities and disease related parameters in multiple sclerosis. J Urol. 1995; 154: 169-173. Go to original source... Go to PubMed...
  8. Mitterberger M, Pinngera GM, Marksteiner R, Margreiter E, Fussenegger M, Frauscher F, Ulmer H, Hering S, Bartch G, Strasser H. Adult stem cell therapy of female stress urinary incontinence. European Urology, 2008; 53: 169-175. Go to original source... Go to PubMed...
  9. Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21. Go to original source... Go to PubMed...
  10. Romžová M, Hurtová M, Pacovský J, Broďák M. Inkontinence moče u neurogenního močového měchýře. Urolog. praxi, 2010; 11(5): 247-252.
  11. Schultz-Lampel D, Thüroff JW. Neurogene systemerkrankungen - Ursachen und Auswirkungen auf die Blassenfunction. Springer. Berlin-Heidelberg-New York. 1997. Go to original source...
  12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285. Go to original source... Go to PubMed...
  13. Vereecken RL, Van Poppel H, Boeckx G, Leuritte A. Long-term alpha-adrenergic blocking therapy in detrusor urethra dyssynergia. Eur Urol 1983; 9: 16. Go to original source... Go to PubMed...
  14. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol. praxi, 2010; 11(5): 241-246.
  15. Vrtal R, Záťura F, Vidlář A. První zkušenosti s užitím duloxetinu u pacientek se stresovou inkontinencí. Ces Urol, 2006; 1: 40-43.
  16. Woodbury MG, Hayes KC, Askes HK. Intermittent catheterization practices following spinal cord injury: a national survey. Can J Urol 2008; 15(3): 4065-4071.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.